Imugene Limited ( (AU:IMU) ) has issued an announcement.
Imugene Limited has announced the clearance of the first dose level in the intravenous combination arm of its Phase 1 onCARlytics trial, known as OASIS, which targets adult patients with advanced or metastatic solid tumors. The trial aims to make solid tumors express the CD19 target, allowing them to be treated with approved CD19 targeting therapies. The trial is being conducted at multiple sites in the U.S., with plans to recruit 40-50 patients. This advancement in the trial marks a significant step in evaluating the safety and efficacy of onCARlytics, potentially impacting the treatment of solid cancers by providing a target for CD19 therapies.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel immunotherapies aimed at activating the immune system to treat and eradicate tumors. The company is leveraging unique platform technologies to harness the body’s immune response against cancer.
YTD Price Performance: 20.0%
Average Trading Volume: 138,874
Technical Sentiment Signal: Buy
Current Market Cap: $150.3M
For an in-depth examination of IMU stock, go to TipRanks’ Stock Analysis page.